IO
IOB.F Ion Beam Applications SA
- Market cap
- EUR 491M
- P/E
- 20.6x
- P/B
- 4.15x
- ROE
- 10.0%
- Dividend yield
- 1.44%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is IOB.F undervalued?
Graham numberIOB.F trades 94.9% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Ion Beam Applications SA fundamental analysis
No fundamental analysis for Ion Beam Applications SA yet.
Ion Beam Applications SA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Ion Beam Applications SA
Ion Beam Applications SA designs, produces, and markets solutions for cancer diagnosis and treatments, serious illnesses, and industrial applications in Belgium, the United States, China, Germany, and India. It operates through four segments, Clinical Proton Therapy; Clinical Dosimetry; IBA Technologies; and IBA Corporate. The company develops ConformalFLASH, a novel technique using the proton Bragg peak; DynamicARC, a technique that allows dynamic spot scanning irradiation …
Full company profileIon Beam Applications SA financial statements
Ion Beam Applications SA annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 313M | 361M | 467M | 498M | 620M |
| Gross Profit | 108M | 127M | 134M | 168M | 200M |
| Operating Income | 13.7M | 4.96M | 5.35M | 9.89M | 22.2M |
| EBITDA | - | 12.3M | 13.2M | 28.8M | 36.5M |
| Net Income | 3.88M | 6.06M | -9.11M | 9.25M | 12.7M |
| EPS | 0.13 | 0.21 | -0.31 | 0.32 | 0.43 |
| Balance Sheet | |||||
| Total Assets | 546M | 624M | 598M | 616M | 691M |
| Total Liabilities | 420M | 508M | 491M | 505M | 563M |
| Shareholders' Equity | 126M | 116M | 106M | 111M | 127M |
| Cash & Short-term Investments | 199M | 158M | 109M | 72.2M | 64.7M |
| Cash Flow | |||||
| Operating Cash Flow | 87.2M | 21.7M | -19.8M | -10.6M | -25.7M |
| Capital Expenditure | 5.03M | 7.33M | 12.3M | 7.42M | 12.7M |
| Free Cash Flow | 82.2M | 14.4M | -32.1M | -18.0M | -38.4M |
| Ratios | |||||
| ROE | 3.1% | 5.2% | -8.6% | 8.3% | 10.0% |
| ROA | 0.7% | 1.0% | -1.5% | 1.5% | 1.8% |
| Net Profit Margin | 1.2% | 1.7% | -2.0% | 1.9% | 2.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Ion Beam Applications SA dividends
- Dividend yield
- 1.44%
- Forward dividend
- 0.25 EUR
- Payout ratio
- 55.4%
- Ex-dividend date
- Jun 15, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 7.06M | 0.24 | 55.4% |
| 2024 | EUR 4.89M | 0.17 | 52.8% |
| 2023 | EUR 6.12M | 0.21 | - |
| 2022 | EUR 5.58M | 0.19 | 92.1% |
| 2021 | EUR 5.79M | 0.20 | 149.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Ion Beam Applications SA
- Insiders 36.61%
- Institutions 21.16%
- Public & others 42.23%
- Shares outstanding 29.0M
- Free float 26.2M
Ion Beam Applications SA company profile
- Company name
- Ion Beam Applications SA
- Ticker
- IOB.F
- ISIN
- BE0003766806
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 2,264
- Fiscal year end
- December
- Address
- 3, Chemin du Cyclotron, Louvain-la-Neuve, Belgium, 1348
- Phone
- 32 1 047 58 11
- Website
- iba-worldwide.com
About Ion Beam Applications SA
Ion Beam Applications SA designs, produces, and markets solutions for cancer diagnosis and treatments, serious illnesses, and industrial applications in Belgium, the United States, China, Germany, and India. It operates through four segments, Clinical Proton Therapy; Clinical Dosimetry; IBA Technologies; and IBA Corporate. The company develops ConformalFLASH, a novel technique using the proton Bragg peak; DynamicARC, a technique that allows dynamic spot scanning irradiation and energy switching while the gantry is rotating; Proteus ONE, a compact proton therapy system transforming cancer treatment; Proteus PLUS, a proton therapy solution for cancer centers; and dosimetry solutions that includes radiation therapy; medical imaging; and QUASAR that offers a portfolio of sophisticated phantoms supporting MR guided radiation therapy, motion management, surface guided radiation therapy, geometric distortion analysis, and machine targeting solutions. It also offers radio pharma solutions, including radioisotopes, cyclotrons, and radiochemistry, as well as other integrated and industrial solutions, and services. In addition, the company is involved in construction of proton therapy, and other accelerators equipment and installation services; and operation and maintenance services, as well as sales a license for intellectual property. The company has strategic research and development partnership with SCK CEN, a Belgian nuclear research center focusing on the development of Actinium-225, a radioactive isotope for the treatment of cancer. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.
Ion Beam Applications SA management
8- Mr. Olivier LegrainCEO, MD & Vice Chairman · born 1968
- Mr. Yves JongenFounder, Chief Research Officer & Executive Director · born 1947
- Ms. Catherine VandenborreCFO, Chief Ventures & Corporate Officer · born 1971
- Mr. Henri de RomreeDeputy CEO, Internal Director & Managing Director · born 1976
- Mr. Thomas PevenageHead of Corporate Finance & Investments
- Olivier LechienCorporate Communication Director
- Thomas CanonSustainability Program Director
- Bruno ScutnairePresident of IBA RadioPharma Solutions